(2025) confirmed these patterns across the drug class: GLP-1 RAs significantly reduce lean mass (mean difference: 0.86 kg ), with the most potent agents for weight losssemaglutide 2.4 mg and tirzepatide 15 mgalso causing the greatest lean mass losses
DavorenAKRulisonKMilroyJGristPFedorukMLewisLet al
Cignas 2026 commercial formulary includes six GLP-1 medications: Wegovy (semaglutide for obesity and CVD), Zepbound (tirzepatide for obesity and OSA), Ozempic (semaglutide for type 2 diabetes), Mounjaro (tirzepatide for type 2 diabetes), Saxenda (liraglutide for obesity), and Rybelsus (oral semaglutide for type 2 diabetes)
Remember, proper blending and administration are crucial
In the absence of ligand, a Negative Regulatory Region (NRR) in the Notch ectodomain adopts an autoinhibited conformation, masking the ADAM cleavage site [1, 2]
Lab Work: Regular lab work helps monitor your health and ensures the treatment is progressing safely and effectively, allowing for proactive adjustments if needed